Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Creative Medical Technology Holdings (CELZ) Debt to Equity (2016 - 2023)

Creative Medical Technology Holdings (CELZ) has disclosed Debt to Equity for 14 consecutive years, with $0.0 as the latest value for Q1 2023.

  • On a quarterly basis, Debt to Equity fell 36.89% to $0.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $0.0, a 36.89% decrease, with the full-year FY2022 number at $0.0, down 35.59% from a year prior.
  • Debt to Equity was $0.0 for Q1 2023 at Creative Medical Technology Holdings, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.0 in Q1 2022 to a low of -$0.85 in Q4 2019.
  • A 5-year average of -$0.22 and a median of -$0.01 in 2020 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: crashed 48521.35% in 2019, then surged 286.91% in 2021.
  • Creative Medical Technology Holdings' Debt to Equity stood at -$0.85 in 2019, then soared by 99.91% to -$0.0 in 2020, then soared by 286.91% to $0.0 in 2021, then plummeted by 35.59% to $0.0 in 2022, then rose by 7.04% to $0.0 in 2023.
  • Per Business Quant, the three most recent readings for CELZ's Debt to Equity are $0.0 (Q1 2023), $0.0 (Q4 2022), and $0.0 (Q3 2022).